Business · 15/03/2016

FDA Announces Public Comment Period for Study on Biosimilar Review Costs

The US Food and Drug Administration (FDA) is seeking public input on the findings of a study assessing the workload volume and full costs associated with reviewing biosimilar biological product applications, as mandated by the Biosimilar User Fee Act of 2012.